---
title: "Vistagen advances Phase 3 SAD trials with 2025 data readout target"
date: "2025-02-14 04:55:33"
summary: "Earnings Call Insights: Vistagen Therapeutics (NASDAQ:VTGN) Q3 2025 Management View CEO Shawn Singh outlined the company’s progress on its lead clinical programs, particularly fasedienol, which is being developed for the acute treatment of social anxiety disorder (SAD). Singh confirmed that the PALISADE-3 and PALISADE-4 Phase 3 trials are advancing, with..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Earnings Call Insights: Vistagen Therapeutics (NASDAQ:[VTGN](https://seekingalpha.com/symbol/VTGN "Vistagen Therapeutics, Inc.")) Q3 2025

### Management View

* CEO Shawn Singh outlined the company’s progress on its lead clinical programs, particularly fasedienol, which is being developed for the acute treatment of social anxiety disorder (SAD). Singh confirmed that the PALISADE-3 and PALISADE-4 Phase 3 trials are advancing, with top-line results expected later in 2025. He emphasized the absence of an FDA-approved medication for this indication and the potential of fasedienol to address a significant unmet need affecting over 30 million adults in the U.S.
* Singh also announced the initiation of an exploratory Phase 2 repeat-dose study for fasedienol, designed to assess the safety and potential efficacy of a second dose, which could inform future labeling.
* Additional updates included progress in the development of itruvone for major depressive disorder, with plans for Phase 2b clinical development in the U.S., and ongoing IND-enabling studies for PH80 targeting menopausal hot flashes.
* CFO Cindy Anderson reported research and development expenses of $11.3 million for the quarter, up from $4.5 million in the same period last year, driven by the PALISADE Phase 3 program and IND-enabling activities for other assets. General and administrative expenses were $4 million, slightly higher than the prior year. Net loss for the quarter was $14.1 million, compared to $6.4 million last year. Cash, cash equivalents, and marketable securities stood at $88.6 million as of December 31, 2024.

### Outlook

* Management reaffirmed their timeline for the PALISADE-3 and PALISADE-4 trials, targeting data readouts in 2025. Both trials aim to provide the evidence required for an NDA submission for fasedienol in 2026. Singh noted that these trials are critical to establishing substantial evidence of the drug’s efficacy and safety profile.
* IND-enabling work for PH80 is expected to conclude by mid-2025, enabling Phase 2 development in the U.S. for the treatment of menopausal hot flashes. Additionally, the Phase 2b protocol for itruvone is in its final stages and could begin soon.

### Financial Results

* Research and development expenses increased significantly year-over-year, primarily due to costs associated with the PALISADE trials and preclinical activities for itruvone and PH80. General and administrative expenses grew modestly, reflecting higher headcount. Cash reserves decreased slightly from the previous quarter but remain strong at $88.6 million, supporting ongoing clinical programs.

### Q&A

* Andrew Tsai, Jefferies: Asked about confidence in the PALISADE trials' execution. Singh highlighted improved protocol adherence, in-person training, and enhanced site monitoring as key factors reducing variability. Josh Prince added that the company has implemented quick intervention and retraining mechanisms for site deviations.
* Matt, Jefferies: Inquired about competition in the SAD market. Singh emphasized the unique nose-to-brain neurocircuitry mechanism of fasedienol, which avoids systemic side effects and offers rapid onset of action, differentiating it from potential competitors.
* John Boyle, William Blair: Questioned the rationale for clinician administration in the PALISADE trials. Prince explained that this approach minimizes variability and ensures consistent drug delivery during the public speaking challenge.
* Emily, Stifel: Asked about the exploratory repeat-dose study. Prince stated that the study aims to determine the safety and potential benefit of a second dose within 10 minutes, which could inform regulatory labeling.

### Sentiment Analysis

* Analysts expressed a neutral to slightly positive tone, focusing on protocol improvements and competitive differentiation in the SAD market. Questions were constructive, seeking clarity on trial execution and potential product positioning.
* Management displayed confidence throughout, particularly in their ability to address variability in clinical trials and the unique mechanism of their intranasal therapies. Singh stated, "We are confident where we stand in terms of time to onset and the ability to avoid issues associated with systemic therapies."
* Compared to the prior quarter, the tone remained consistent, with a continued emphasis on the progress of the PALISADE trials and the broader pipeline.

### Quarter-over-Quarter Comparison

* Guidance for PALISADE-3 and PALISADE-4 remained unchanged, with both trials on track for 2025 data readouts. This quarter saw enhanced focus on trial execution improvements, such as in-person training and site monitoring.
* Research and development expenses increased from the prior quarter due to intensified clinical activity, while cash reserves decreased slightly.
* Analysts maintained their focus on the critical Phase 3 trials, with additional inquiries about competition and potential regulatory strategies.

### Risks and Concerns

* Management identified no significant risks to the PALISADE trials' timelines but underscored the importance of strict protocol adherence to minimize variability.
* Analysts raised concerns about potential competition in the SAD market, though Singh emphasized the unique mechanistic approach of fasedienol as a differentiator.
* Regulatory risk was discussed in the context of the exploratory repeat-dose study, but management expressed confidence in the safety profile of fasedienol based on prior data.

### Final Takeaway

Vistagen Therapeutics continues to advance its clinical pipeline, with a focus on addressing unmet needs in neuroscience through its innovative intranasal therapies. The company remains on track for critical 2025 data readouts from its Phase 3 trials in social anxiety disorder, while also progressing its IND-enabling studies for additional assets. Management’s confidence in execution and differentiation highlights the potential for significant shareholder value creation.

[Read the full Earnings Call Transcript](https://seekingalpha.com/symbol/VTGN/earnings/transcripts)

[seekalpha](https://seekingalpha.com/news/4408325-vistagen-advances-phase-3-sad-trials-with-2025-data-readout-target)
